| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CKS1B |
| Uniprot No | P61024 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-79aa |
| 氨基酸序列 | MGSSHHHHHH SSGLVPRGSH MGSMSHKQIY YSDKYDDEEF EYRHVMLPKD IAKLVPKTHL MSESEWRNLG VQQSQGWVHY MIHEPEPHIL LFRRPLPKKP KK |
| 预测分子量 | 12 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CKS1B重组蛋白的参考文献示例(注：文献为虚构示例，实际文献需通过学术数据库查询)：
---
1. **标题**: *"Expression and Purification of Recombinant Human CKS1B for Functional Studies"*
**作者**: Li, X. et al.
**摘要**: 描述了在大肠杆菌系统中表达和纯化重组人CKS1B蛋白的方法，验证了其与CDK2的相互作用，并证明其在细胞周期调控中的功能活性。
2. **标题**: *"Structural Insights into CKS1B Recombinant Protein Binding to CDK1/2 Kinases"*
**作者**: Martinez, R. & Kumar, S.
**摘要**: 通过X射线晶体学解析了重组CKS1B与CDK1/2复合物的结构，揭示了其结合界面和细胞周期调控的分子机制。
3. **标题**: *"CKS1B Recombinant Protein Enhances Proteasome Activity in Multiple Myeloma Models"*
**作者**: Chen, H. et al.
**摘要**: 研究重组CKS1B蛋白在多发性骨髓瘤细胞中的作用，发现其过表达通过泛素-蛋白酶体通路加速癌蛋白降解，促进疾病进展。
4. **标题**: *"Development of a CKS1B-Based Biosensor Using Recombinant Protein Technology"*
**作者**: Park, J. et al.
**摘要**: 利用重组CKS1B蛋白构建细胞周期监测生物传感器，实时追踪CDK活性变化，为抗癌药物筛选提供新工具。
---
**建议**：实际文献可通过PubMed或Google Scholar搜索关键词(如“CKS1B recombinant protein”、“CKS1B purification”、“CKS1B CDK interaction”)获取，重点关注细胞周期、癌症或蛋白互作领域的研究。
CKS1B (CDC28 protein kinase regulatory subunit 1B) is a member of the highly conserved CKS protein family, which plays critical roles in cell cycle regulation. It functions as a regulatory subunit for cyclin-dependent kinases (CDKs), particularly interacting with CDK1 (CDC2) and CDK2. CKS1B facilitates the G1/S phase transition and mitotic exit by modulating CDK activity and substrate recognition. Structurally, it contains a conserved "CKS domain" that enables binding to phosphorylated CDKs and other cell cycle proteins.
In cancer biology, CKS1B is recognized for its oncogenic potential. Overexpression of CKS1B is observed in multiple malignancies, including breast cancer, glioblastoma, and multiple myeloma, where it correlates with poor prognosis. It promotes tumor progression by enhancing the ubiquitin-mediated degradation of cell cycle inhibitors like p27Kip1 through interactions with the SCF-Skp2 ubiquitin ligase complex. This activity drives uncontrolled cell proliferation and chemoresistance.
Recombinant CKS1B protein is produced using expression systems like *E. coli* or mammalian cells, followed by purification via affinity chromatography. It serves as a vital tool for studying protein-protein interactions, kinase regulation, and drug screening. Researchers utilize it to investigate CKS1B's role in cancer mechanisms, validate therapeutic targets, or develop diagnostic assays. Inhibitors targeting CKS1B-CDKN1B/p27Kip1 pathways are under exploration for anticancer therapies.
Overall, CKS1B recombinant protein bridges basic research and clinical applications, offering insights into cell cycle dysregulation in diseases while supporting the development of targeted interventions.
×
